Introduction
Chlorhexidine gluconate (CHG) is a topical broad-spectrum antiseptic used frequently to control antibiotic resistant bacteria and prevent infections. 1 CHG skin cleansing before central venous catheter insertion compared with povidone iodine reduces rates of catheter-related bloodstream infections. 2 As a result, the Centers for Disease Control and Prevention recommend skin preparation with chlorhexidine before placement of central venous catheters. 3 However, because of limited safety data 'no recommendation can be made for the safety or efficacy of chlorhexidine in infants aged <2 months'. 3 CHG has been shown to be safe and well tolerated in term neonates exposed to chlorhexidine by different methods, including via vaginal washings, umbilical cord cleansing and whole body cleansing. 4 Although there is some evidence documenting the safety of CHG in term infants, there is still a gap in the existing data regarding the safety and impact of CHG in preterm infants.
Preterm infants, especially those <32 weeks gestation, have immature skin with increased permeability, vulnerable developing neurological systems and metabolic limitations resulting in decreased drug clearance; all of which might predispose them to a higher rate of adverse reactions from CHG. We review the current data about CHG use in this susceptible population, focusing on neonates <32 weeks gestation and highlighting the two biggest areas of concern, skin toxicity and systemic absorption following topical use.
Historical perspective on CHG safety in neonates
The safety of CHG for use as a one-time skin scrub or full body bath has been studied since the 1970s. 5 Although uncommon, skin irritation, including contact dermatitis and photosensitization, are the most common adverse reactions. Rare cases of hypersensitivity and anaphylaxis have also been reported. 6 Trace amounts of CHG can be absorbed through the skin after a single bath in adults and term neonates. [7] [8] [9] [10] [11] [12] [13] There are no reports of adverse consequences as a result of trace chlorhexidine absorption in studies of term newborns or adults, and no data to suggest that trace levels have clinical importance. 4 There are limited data available in premature infants, however. Following the finding in the 1970s that hexachlorophene, another topical antiseptic, was absorbed through the skin of newborns and caused vacuolar encephalopathy, [14] [15] [16] chlorhexidine has been scrutinized for its potential to be absorbed through the skin. Hexachlorophene and chlorhexidine are both phenol derivatives, however, hexachlorophene is a chlorinated bisphenol and chlorhexidine is a chlorinated cationic biguanide ( Figure 1 ). Hexachlorophene is bacteriostatic, disrupting the cell wall with a slow onset of action only effective against Gram-positive organisms. Chlorhexidine is bacteriocidal, increasing cell membrane permeability with a more rapid onset of action and is effective against both Gram-positive and Gram-negative bacteria. 17 Both products leave a residue on the skin; however, hexachlorophene requires multiple applications for maximal antibacterial effect and is easily removed by alcohol. Chlorhexidine more strongly binds to protein in the outermost layer of the skin, withstanding removal by alcohol and immediately decreasing organisms on the skin after one application. 18 Although numerous studies have assessed CHG absorption in term infants with no reports of neurotoxicity, residual concerns have limited its use in some hospitalized neonates, especially low birth weight preterm infants. 19 This population with increased vulnerability to infection may benefit from the antiseptic effects of CHG. However, this population may also be at a higher risk for skin absorption and adverse reactions including skin toxicity and potential unforeseen neurotoxicity.
Use of CHG in neonates
Despite the lack of safety data in preterm infants, CHG is commonly used in NICU populations in the United States. The frequent use was recently measured in a survey of 100 NICU training program directors. 19 In all, 61% (55 of 90) of the participants reported using chlorhexidine in their NICU, with the most common use being skin preparation during central venous catheter dressing changes ( Figure 2 ). Of those NICUs who use CHG, 51% reported restricting use by birth weight, gestational age or chronological age; implying that 49% may be using CHG on children of any birth weight, gestational age or chronological age. Adverse reactions involving the skin were reported by 28 of the 55 (51%) NICUs using CHG, but no NICUs reported systemic toxicities. The most common adverse reaction was skin burns with erythema being second most common. A total of 13 of the 17 centers reporting burns noted that the burns occurred in neonates with birth weights <1500 g; the other four centers did not mention birth weights.
Skin toxicity associated with CHG use Skin toxicity is a significant area of concern in preterm low-birth weight infants exposed to CHG. Skin burns in the neonate can lead to hypothermia, excessive water loss, sepsis and renal failure. 20 Concerns regarding skin breakdown were the most common reservations neonatologists cited for their hesitation to use CHG. 19 A number of studies evaluating CHG as an antiseptic have included preterm infants and have described adverse events ( Table 1) . Garland et al.
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reported severe contact dermatitis with the use of a CHG-impregnated dressing that was placed over catheter sites after insertion. During the study period, 15 (15%) of 98 infants <1000 g and 4 (1.5%) of 237 infants X1000 g who received the CHG dressing developed related contact dermatitis under the dressing. 22 Most episodes of dermatitis occurred in neonates who were <28 weeks gestation at birth and less than a week old. These episodes of dermatitis may have been secondary to CHG, but some have suggested that external pressure from an occlusive adhesive dressing may restrict capillary perfusion to the skin and cause local skin breakdown. 23 Contact dermatitis has not been reported in infants receiving full-body CHG skin cleansing when occlusive dressings were not necessary, even for very low birth weight infants and neonates as young as 28 weeks gestational age. 8 Alcohol-based CHG preparations have been reported to cause burns in infants 24 to 26 weeks gestational age. 20,24 -26 Alcohol alone is a known cause of skin burns in preterm infants, 27 therefore the impact of CHG as the trigger of skin breakdown in alcohol-based CHG preparations is unknown. One study of a 2% aqueous topical CHG solution in neonates <1000 g and <48 h of age noted that 4 of 36 (11%) developed severe skin irritation; 3 of 4 were noted to have erythema alone but one infant developed skin breakdown and exudation. 28 A recent case report also identified an infant born at 25 weeks gestation who sustained skin burns after exposure to a 2% aqueous CHG solution before umbilical catheter placement in the first few hours of life. 29 The most common reported event after CHG exposure is skin irritation. In most cases, whether this irritation is caused by true allergy, hypersensitivity reaction, occlusive dressings or the alcohol-based solution is unknown. If CHG is going to be used frequently in preterm infants, it is important to identify which component, the CHG or the ethanol, causes skin irritation in this population and to develop formulations of CHG products that can be more safely administered to these infants. 
Potential absorption of CHG
Another area of concern in preterm infants exposed to CHG is the increased potential for CHG absorption. The skin of preterm infants is immature, with poor cohesion of the dermis to the epidermis and a thinner, poorly formed stratum corneum. The stratum corneum, the outermost layer of the skin, is only 2 to 3 cell layers thick at 23 weeks gestation and is not well developed until around 34 weeks of gestation. 30 It is essential for creating an effective epidermal barrier. Without this effective barrier, preterm infants are at risk for increased absorption of potentially poisonous substances, as well as increased susceptibility to skin damage, infection and water loss. 31 Postnatally, the epidermal barrier of preterm infants matures to that of a term infant over 2 to 3 weeks. 30 Although several studies have shown CHG absorption levels in term neonates comparable to those in adults, there are little data documenting CHG absorption in preterm neonates. The immature epidermal barrier in preterm infants has fueled concerns that preterm infants are at increased risk for CHG absorption after exposure. Increased absorption of CHG, along with the metabolic limitations and developing organ systems of preterm infants, might potentiate adverse events not seen in adults or even term infants.
There are limited data addressing the potential for chlorhexidine absorption following topical application in preterm infants, especially in those <32 weeks gestation in the first 2 weeks of life. Three studies have reported detectable chlorhexidine concentrations in the blood of preterm infants <32 weeks gestation after skin exposure to CHG. [7] [8] [9] In a study by Cowen et al. in 1979, blood samples were taken from 34 infants after whole body bathing with Hibiscrub (Mölnlycke Health Care, Gothenburg, Sweeden), a 4% CHG aqueous solution not marketed in the United States, to determine if chlorhexidine was absorbed percutaneously. 8 Infants were bathed once daily by applying Hibiscrub to the whole body except the face and then washing the Hibiscrub off with plain water. The gestational age of the infants ranged from 28 to 39 weeks. A total of 17 infants had chlorhexidine levels drawn after the first bath. All 10 infants who had blood samples taken via heel stick had detectable chlorhexidine concentrations in their blood compared with only 3 of 7 infants who had blood samples drawn via venipuncture. The authors speculate that detectable CHG may have resulted from contamination of the sample by residual chlorhexidine on the skin after bathing. The other 17 infants in the study were bathed daily over a period of time ranging from 4 to 32 days and had levels drawn after the first bath and at weekly intervals to assess for chlorhexidine accumulation. Only 2 of those 17 infants whose blood samples were drawn via venipuncture had detectable blood concentrations of chlorhexidine. No accumulation was seen in these infants. In total, five infants who had blood samples drawn via venipuncture had detectable chlorhexidine concentrations after exposure and all of those infants were <36 weeks gestation. Of all 34 infants enrolled in the study, only 8 were <32 weeks gestation and only 1 of those infants had a blood sample drawn within the first 2 weeks of life when the skin permeability is higher compared with a term infant. No adverse events were reported in this study.
In 1981, Aggett et al. 7 assessed CHG absorption in 25-term infants and 23-preterm infants with gestational ages between 31 to 36 weeks. After birth, the infants had repeated treatments of a 1% CHG in ethanol solution and a 1% CHG with 3% zinc oxide powder placed on their umbilical cord stumps every 4 h for at least 9 days. The 1% CHG in ethanol solution was also used for all invasive procedures the infant received, with the exception of venipuncture. Of note, the ethanol concentration used in the 1% CHG solution was not documented in the paper. Significantly higher concentrations of chlorhexidine were seen in the preterm infants compared with the term infants on days 5 and 9, as well as a significant increase in chlorhexidine concentrations from day 5 to day 9 in the preterm infants, suggesting possible accumulation. A subsequent study was performed given these findings, using only the CHG and zinc oxide powder for umbilical cord treatments and using the 1% CHG in ethanol solution only for invasive procedures. Blood samples were taken from 29 preterm infants, ranging from 26 to 36 weeks gestation. A total of 10 of these infants, all p34 weeks gestation, had detectable chlorhexidine concentrations on days 5 and/or 9. Although there were no adverse events reported this study demonstrated increased absorption in preterm infants compared with term infants.
A pilot study by Garland et al. 9 in 2009 enrolled 48 infants to compare tolerance of 2% CHG in 70% isopropyl alcohol and 10% povidone-iodine used for skin antisepsis before percutaneously inserted central catheter placement and with subsequent dressing changes. Because of concerns for contact dermatitis, infants <7 days old and with weights <1500 g were excluded. In all, 10 infants had blood samples measured for CHG. Five of these infants were <32 weeks gestation. Of these five infants, four had measurable concentrations of CHG in their blood. The concentrations increased with repeated exposure on at least one occasion in all of these infants. One infant born at 27 weeks gestation did not have CHG detected but was 53 days old at the time of exposure. Only one infant <32 weeks gestation had blood drawn within the first 2 weeks of life; no CHG was detected in the first blood sample, however, CHG concentrations were detected in the subsequent two samples, which were collected after additional CHG exposure 24 h and 7 days, respectively, after the initial exposure. No contact dermatitis was reported or any other adverse events.
In aggregate, blood concentrations of CHG have been reported in 17 patients born <32 weeks gestation ( Table 2 ). The chlorhexidine concentrations ranged from 0 to 214 ng ml À1 . None of the 17 subjects were <27 weeks gestation and only 5 had chlorhexidine levels drawn within the first 2 weeks of life, when the epidermal barrier is most compromised. From these 5 patients, there were 11 samples collected within 14 days of life. Of all, 6 of 11 samples had detectable concentrations (mean 23, median 16, and range 0 to 92 ng ml À1 ). Two of the studies used chlorhexidine in an alcohol-based solution and one used an aqueous formulation. Alcohol is known to potentiate the absorption of topically applied solutions 7 and it is possible that alcohol increased the absorption of CHG in those patients, however, this does not explain the notable CHG concentrations in the patients only exposed to an aqueous formulation. From all three studies reporting CHG absorption in preterm infants, there were no reports of severe adverse reactions in the patients, including no neurological complications or skin toxicity.
The clinical significance of detecting CHG in the blood is unknown. There are no established values for what is considered to be a safe concentration of CHG in the blood. There are no reports of adverse health consequences as a result of absorption of CHG in neonates. In vitro studies have demonstrated CHG-induced toxicity to various cell lines, including odontoblasts, fibroblasts, human epithelial cells and erythrocytes following direct exposure to CHG concentrations as low as 0.04%. [32] [33] [34] [35] One study investigating the toxicity of certain antiseptics when placed on human skin substitute reported moderate cytotoxic effects from chlorhexidine, which were significantly less than the cytotoxic effects observed from Betadine. 36 An in vivo study using a rat model showed toxicity to adrenergic neurons after direct exposure to CHG via intraocular injection. 37 Potential neurotoxicity has also been suggested by a recent in vitro study demonstrating inhibition of L1-mediated neurite outgrowth after direct exposure to CHG. 38 The clinical correlation of these studies is unclear, however. Although animal studies have reported lethal doses of chlorhexidine following oral ingestion or intravenous administration, 39 there are no reports describing correlated serum concentrations in animals following these lethal challenges. Comparison of reported blood concentrations of CHG amongst different studies is difficult because the samples were collected differently (heel stick versus venipuncture) and different laboratory assays were used for measurement. A standard assay to detect CHG in the blood does not exist. In addition, the strength of CHG in solution that is both effective and non-toxic when applied topically is not known. Blood concentrations of CHG may correlate with the strength of topical CHG solution used, as neonates exposed to 1% CHG had significantly higher blood concentrations of chlorhexidine compared with neonates exposed to 0.25 and 0.5% CHG solutions. 11 
Conclusion
As CHG becomes more widely used to prevent infections in hospitalized patients, more data are needed to further explore skin toxicity and CHG absorption through the skin into the bloodstream in preterm infants, especially those <32 weeks gestation and within the first 2 weeks of life. Future studies should identify differences in absorption potential between alcoholic and aqueousbased CHG solutions. In light of the documented absorption that has been seen, additional research on the potential toxicity to the developing neurological system is needed to establish an appropriate threshold for serum chlorhexidine concentrations. Future studies should also evaluate the potential for accumulation of chlorhexidine in the blood with repeated exposure, which has been suggested in preterm neonates 7 but not found in older infants and children. 40 There are many NICUs across the US routinely using CHG in preterm infants, a population in which the US FDA (Food and Drug Administration) has not approved its use. Although there may be antiseptic benefits of CHG use in this population, more data on these vulnerable, high-risk preterm infants are needed to establish safety or warn of potential toxicity.
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